<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="description" content="Data analytics portfolio project analyzing $3.84 billion in potential Medicare Part D savings through increased generic drug adoption. Analysis of 2023 prescriber data by Aiden, showcasing Python and Tableau skills.">
    <title>The $3.84 Billion Question: Medicare Part D Generic Drug Analysis</title>
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Cormorant+Garamond:wght@300;400;600;700&family=Work+Sans:wght@300;400;500;600&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="medicare-partd-style.css">
</head>
<body>
    <nav class="portfolio-nav">
        <div class="nav-container">
            <a href="https://aidenjajo.com" class="nav-logo">Aiden Jajo</a>
            <div class="nav-links">
                <a href="https://aidenjajo.com#projects" class="nav-link">← Back to Portfolio</a>
                <a href="#sources" class="nav-link">Sources</a>
            </div>
        </div>
    </nav>
    <section class="hero">
        <div class="hero-content">
            <h1 class="hero-title">The $3.84 Billion Question</h1>
            <p class="hero-subtitle">Analyzing Generic Drug Adoption in Medicare Part D<br>A Data Analytics Portfolio Project | February 2026</p>
            <div class="hero-stats">
                <div class="big-stat">$3.84B</div>
                <p class="stat-description">Potential annual Medicare savings from just 25% brand to generic conversion in 2023</p>
            </div>
            <div class="tableau-viz" id="kpi-summary" style="margin-top: 3rem;">
                <div class='tableauPlaceholder' id='viz1770612509057' style='position: relative'><noscript><a href='#'><img alt='KPI - Summary Statistics ' src='https:&#47;&#47;public.tableau.com&#47;static&#47;images&#47;KP&#47;KPI-SummaryStatistics&#47;Sheet1&#47;1_rss.png' style='border: none' /></a></noscript><object class='tableauViz'  style='display:none;'><param name='host_url' value='https%3A%2F%2Fpublic.tableau.com%2F' /> <param name='embed_code_version' value='3' /> <param name='site_root' value='' /><param name='name' value='KPI-SummaryStatistics&#47;Sheet1' /><param name='tabs' value='no' /><param name='toolbar' value='yes' /><param name='static_image' value='https:&#47;&#47;public.tableau.com&#47;static&#47;images&#47;KP&#47;KPI-SummaryStatistics&#47;Sheet1&#47;1.png' /> <param name='animate_transition' value='yes' /><param name='display_static_image' value='yes' /><param name='display_spinner' value='yes' /><param name='display_overlay' value='yes' /><param name='display_count' value='yes' /><param name='language' value='en-US' /></object></div>
                <script type='text/javascript'>
                    var divElement = document.getElementById('viz1770612509057');
                    var vizElement = divElement.getElementsByTagName('object')[0];
                    vizElement.style.width='100%';
                    vizElement.style.height=(divElement.offsetWidth*0.75)+'px';
                    var scriptElement = document.createElement('script');
                    scriptElement.src = 'https://public.tableau.com/javascripts/api/viz_v1.js';
                    vizElement.parentNode.insertBefore(scriptElement, vizElement);
                </script>
            </div>
        </div>
    </section>
    <section id="introduction">
        <div class="container">
            <h2>Introduction</h2>
            <p>In 2023, Medicare Part D spent $57.3 billion on medications that had cheaper, medically identical alternatives sitting on pharmacy shelves. My analysis found that if just 25% of those brand name prescriptions had been switched to their FDA-approved generic equivalents, Medicare could have saved $3.84 billion in a single year.</p>
            <p>Medicare Part D, which began providing prescription drug coverage in 2006, serves approximately 54.8 million Medicare beneficiaries as of 2025.<a href="#source-1" class="citation" title="KFF, October 2025">1</a> When the FDA approves a generic drug as "therapeutically equivalent" to a brand name drug, these products are pharmaceutically equivalent and bioequivalent. They deliver identical amounts of active ingredient into the bloodstream at the same rate.<a href="#source-3" class="citation" title="FDA Orange Book Guidance">3</a> Generics typically cost 80-85% less than their brand name counterparts,<a href="#source-6" class="citation" title="U.S. Pharmacist, June 2020">6</a> and from 2009 to 2018, the U.S. healthcare system saved nearly $2 trillion through generic drug use.<a href="#source-7" class="citation" title="U.S. Pharmacist, June 2020">7</a></p>
            <p>As a pharmacy clerk, I've watched patients struggle with medication costs while standing just feet away from cheaper alternatives that would work exactly the same way. This portfolio project emerged from that experience, using data analytics to quantify a problem I've seen firsthand: why do Medicare beneficiaries continue receiving expensive brand name drugs when identical generic options exist?</p>
            <p>This analysis examines 2023 Medicare Part D prescriber data, a critical year to understand because it represents the landscape just before major policy reforms took effect. The Inflation Reduction Act's redesign of Medicare Part D introduced transformative changes in 2024-2025, including elimination of the coverage gap, implementation of a $2,000 annual out of pocket cap (indexed to $2,100 for 2026), and the Medicare Drug Price Negotiation Program.<a href="#source-10" class="citation" title="CMS Part D Proposed Rule">10</a><a href="#source-11" class="citation" title="CMS 2026 Policy Updates">11</a><a href="#source-12" class="citation" title="KFF Snapshot, October 2025">12</a> What you're seeing here is a historical analysis: what the generic adoption opportunity looked like before these structural reforms fundamentally altered the program.</p>
            <p>Using two CMS datasets containing prescriber level and drug level data, my analysis identified 454 medications with both brand and generic versions available in 2023. The findings reveal not just the scale of the savings opportunity, but where it's concentrated, and the answers are surprising.</p>
        </div>
    </section>
    <section id="the-problem">
        <div class="container">
            <h2>The Problem: When Cheaper Equals Better</h2>
            <h3>The FDA Standard</h3>
            <p>Not all generic drugs are created equal in the eyes of the FDA. When a generic drug receives an "A" rating in the FDA's Orange Book (officially called "Approved Drug Products with Therapeutic Equivalence Evaluations"), it means the generic is deemed therapeutically equivalent to the brand name reference drug and can be safely substituted.<a href="#source-5" class="citation" title="Congress.gov CRS Report">5</a> This rating isn't given lightly: bioequivalence is established when the 90% confidence intervals for the generic to brand ratios of both maximum drug concentration (Cmax) and area under the plasma concentration time curve (AUC) lie within 80-125%.<a href="#source-4" class="citation" title="Rx-wiki Orange Book">4</a></p>
            <h3>What This Means in Practice</h3>
            <p>In simpler terms: FDA-approved therapeutically equivalent generics deliver the same amount of active ingredient into your bloodstream at the same rate as the brand name drug.<a href="#source-3" class="citation" title="FDA Orange Book Guidance">3</a> Same clinical outcome, same safety profile, same effectiveness. The only differences are typically inactive ingredients (like fillers or dyes) and the price.</p>
            <h3>The Price Paradox</h3>
            <p>Here's where it gets interesting: generic drugs typically cost 80-85% less than their brand name counterparts.<a href="#source-6" class="citation" title="U.S. Pharmacist, June 2020">6</a> That's not a small discount. It's a massive price differential for medications the FDA has certified as medically identical. My analysis found that in 2023, this price gap created a $57.3 billion opportunity across just 454 drugs where both brand and generic versions existed.</p>
            <h3>Why This Matters for Medicare</h3>
            <p>When Medicare pays for a brand name drug instead of its generic equivalent, the program spends more money for the same health outcome. Unlike individual patients who might have copay structures that mask the true cost difference, Medicare bears the full price differential. Over time, these choices compound: small decisions by individual prescribers aggregate into billions of dollars in excess spending across the program.</p>
        </div>
    </section>
    <section id="context-2023">
        <div class="container">
            <h2>The 2023 Context: A Snapshot Before Reform</h2>
            <h3>Why 2023 Matters</h3>
            <p>This analysis examines 2023 data, not because it's the most current, but because it captures a critical moment in Medicare Part D history. In January 2023, the Inflation Reduction Act's $35-per-month insulin cost cap took effect for Medicare Part D enrollees,<a href="#source-8" class="citation" title="ASPE HHS, October 2023">8</a> representing the federal government's first major intervention to directly limit out of pocket costs for a specific drug category. Research had shown that 1.5 million Medicare beneficiaries using insulin would have saved $734 million in Part D costs if the cap had been in effect in 2020.<a href="#source-9" class="citation" title="ASPE HHS, October 2023">9</a></p>
            <h3>The Policy Landscape Shifted Dramatically</h3>
            <p>Between 2023 (when this data was collected) and 2026 (when this analysis is being conducted), Medicare Part D underwent transformative structural changes under the IRA:<a href="#source-10" class="citation" title="CMS Part D Proposed Rule">10</a><a href="#source-11" class="citation" title="CMS 2026 Policy Updates">11</a><a href="#source-12" class="citation" title="KFF Snapshot, October 2025">12</a></p>
            <ul>
                <li>Elimination of the coverage gap phase (effective 2025)</li>
                <li>Implementation of a $2,000 annual out of pocket cap for beneficiaries (2025, indexed to $2,100 for 2026)</li>
                <li>Introduction of the Medicare Drug Price Negotiation Program, with negotiated prices for the first 10 selected drugs taking effect January 1, 2026</li>
                <li>Changes to the Manufacturer Discount Program and reinsurance payment methodologies</li>
            </ul>
            <h3>What Changed for Insulin Specifically</h3>
            <p>The insulin market saw particularly dramatic shifts after 2023. Following Medicare's $35 cap, major manufacturers (Eli Lilly, Novo Nordisk, Sanofi) announced voluntary $35 cap programs for uninsured and commercially insured patients in 2023-2024.<a href="#source-23" class="citation" title="PBS NewsHour, January 2024">23</a> By 2025-2026, the Medicare Drug Price Negotiation Program's Selected Drug Subsidy provisions began affecting insulin pricing dynamics.<a href="#source-12" class="citation" title="KFF Snapshot, October 2025">12</a> These changes fundamentally altered the cost sharing landscape that existed when this data was collected.</p>
            <h3>What This Means for the Analysis</h3>
            <p>This project should be understood as historical analysis: what Medicare Part D spending and savings opportunities looked like <em>before</em> these major policy changes took effect. The brand versus generic utilization patterns identified here may have shifted as the IRA provisions were implemented. However, understanding the prereform baseline is critical for evaluating whether policy changes actually moved the needle on generic adoption, and whether the core problem of prescribers choosing expensive brands over identical generics has been addressed or merely masked by cost caps and price negotiations.</p>
        </div>
    </section>
    <section id="the-analysis">
        <div class="container">
            <h2>The Analysis: My Approach</h2>
            <h3>Data Sources</h3>
            <p>This project utilized two publicly available Centers for Medicare & Medicaid Services (CMS) datasets from 2023: the Medicare Part D Prescriber by Drug and Geography dataset (containing prescriber level information on drug spending, claims, and beneficiary counts) and the Medicare Part D Spending by Drug dataset (containing drug level aggregate spending data). Together, these datasets provide comprehensive coverage of Medicare Part D prescription activity across all 50 states plus U.S. territories.</p>
            <h3>Four-Phase Methodology</h3>
            <p>My analysis followed a systematic approach across four phases:</p>
            <p><strong>Phase 1: Drug Identification</strong> &mdash; I identified all drugs with both brand and generic versions available in 2023 and classified drug types based on naming patterns (insulin products, drugs ending in -prazole, -statin, etc.). All generic equivalents were verified against FDA Orange Book therapeutic equivalence standards.<a href="#source-3" class="citation" title="FDA Orange Book Guidance">3</a><a href="#source-5" class="citation" title="Congress.gov CRS Report">5</a></p>
            <p><strong>Phase 2: Utilization Analysis</strong> &mdash; I calculated brand utilization rates (the percentage of prescriptions filled with brand name versions when generics existed) for each drug, computed total Medicare Part D spending on drugs with generic alternatives, and analyzed geographic variation in generic adoption rates across all states and territories.</p>
            <p><strong>Phase 3: Savings Calculation</strong> &mdash; I modeled potential savings at various brand to generic conversion rates (10%, 25%, 50%, 75%, 100%) using the formula: Savings = Brand Spending × Conversion Rate × Generic Discount Rate. The calculations used conservative estimates based on documented generic cost differentials.<a href="#source-6" class="citation" title="U.S. Pharmacist, June 2020">6</a></p>
            <p><strong>Phase 4: Data Validation</strong> &mdash; I verified mathematical consistency across all calculations, cross-referenced totals against CMS published spending figures, and ensured all outputs maintained referential integrity.</p>
            <h3>Tools and Technology</h3>
            <p>All data processing was conducted using Python, with analysis organized into seven separate scripts for transparency and reproducibility. The processed data produced seven Tableau-ready CSV files covering top savings opportunities, conversion scenarios, state level analysis, and drug specific breakdowns. Tableau was used for all visualization and dashboard creation.</p>
        </div>
    </section>
    <section id="finding-1">
        <div class="container">
            <h2>Key Finding #1: The Overall Opportunity</h2>
            <h3>The Headline Number</h3>
            <p>In 2023, Medicare Part D's total gross spending across all drugs reached approximately $275.8 billion. My analysis found that $57.3 billion of this total (20.8%) was spent on 454 drugs that had both brand and generic versions available. This means more than one in every five dollars Medicare spent on prescription drugs went to medications where therapeutically equivalent, significantly cheaper alternatives existed.</p>
            <h3>The 25% Conversion Scenario</h3>
            <p>If just 25% of brand name prescriptions for these 454 drugs had been converted to their generic equivalents in 2023, Medicare could have saved $3.84 billion. This is a conservative scenario, not wholesale replacement of all brand name drugs, but a modest shift toward greater generic adoption. It assumes that three out of every four brand prescriptions would continue unchanged, with only one in four switching to the generic version.</p>
            <h3>Savings at Scale</h3>
            <p>The savings potential scales significantly at higher conversion rates. My analysis modeled five scenarios:</p>
            <ul>
                <li><strong>10% conversion:</strong> $1.54 billion saved annually</li>
                <li><strong>25% conversion:</strong> $3.84 billion saved annually</li>
                <li><strong>50% conversion:</strong> $7.68 billion saved annually</li>
                <li><strong>75% conversion:</strong> $11.52 billion saved annually</li>
                <li><strong>100% conversion:</strong> $15.36 billion saved annually</li>
            </ul>
            <p>Even modest increases in generic adoption (shifting just one in ten brand prescriptions to generic) would generate over $1.5 billion in annual Medicare savings.</p>
            <div class="tableau-viz" id="savings-scenarios">
                <div class='tableauPlaceholder' id='viz1770612605762' style='position: relative'><noscript><a href='#'><img alt='Projected Medicare Savings from Increased Generic Drug Adoption ' src='https:&#47;&#47;public.tableau.com&#47;static&#47;images&#47;Sa&#47;Savings_17706123109360&#47;SavingsScenarios&#47;1_rss.png' style='border: none' /></a></noscript><object class='tableauViz'  style='display:none;'><param name='host_url' value='https%3A%2F%2Fpublic.tableau.com%2F' /> <param name='embed_code_version' value='3' /> <param name='site_root' value='' /><param name='name' value='Savings_17706123109360&#47;SavingsScenarios' /><param name='tabs' value='no' /><param name='toolbar' value='yes' /><param name='static_image' value='https:&#47;&#47;public.tableau.com&#47;static&#47;images&#47;Sa&#47;Savings_17706123109360&#47;SavingsScenarios&#47;1.png' /> <param name='animate_transition' value='yes' /><param name='display_static_image' value='yes' /><param name='display_spinner' value='yes' /><param name='display_overlay' value='yes' /><param name='display_count' value='yes' /><param name='language' value='en-US' /></object></div>
                <script type='text/javascript'>
                    var divElement = document.getElementById('viz1770612605762');
                    var vizElement = divElement.getElementsByTagName('object')[0];
                    vizElement.style.width='100%';
                    vizElement.style.height=(divElement.offsetWidth*0.75)+'px';
                    var scriptElement = document.createElement('script');
                    scriptElement.src = 'https://public.tableau.com/javascripts/api/viz_v1.js';
                    vizElement.parentNode.insertBefore(scriptElement, vizElement);
                </script>
            </div>
            <h3>What This Represents</h3>
            <p>These aren't theoretical savings from unproven interventions or experimental drugs. This is money Medicare could have saved in 2023 by using medications the FDA has already certified as therapeutically equivalent to the brand name versions.<a href="#source-3" class="citation" title="FDA Orange Book Guidance">3</a><a href="#source-5" class="citation" title="Congress.gov CRS Report">5</a> The infrastructure exists, the medications are approved and available, and the clinical outcomes are identical. The question isn't whether generic substitution works. It's why it isn't happening more often.</p>
        </div>
    </section>
    <section id="finding-2">
        <div class="container">
            <h2>Key Finding #2: The Top 20 Drugs</h2>
            <h3>Where the Savings Are Concentrated</h3>
            <p>The $3.84 billion savings opportunity wasn't evenly distributed across all 454 drugs. My analysis found that the top 20 drugs by savings potential accounted for a disproportionate share of the opportunity. What's striking isn't just the concentration. It's <em>which</em> drugs dominated the list.</p>
            <h3>The Insulin Dominance</h3>
            <p>Three insulin products claimed the top three positions:</p>
            <ol>
                <li><strong>Insulin Lispro:</strong> $434.4 million potential savings (25% conversion) with 93% brand utilization</li>
                <li><strong>Insulin Aspart:</strong> $407.2 million potential savings with 98% brand utilization</li>
                <li><strong>Insulin Degludec:</strong> $377.0 million potential savings with 99% brand utilization</li>
            </ol>
            <p>Combined, these three insulin formulations alone represented over $1.2 billion in potential savings from just a 25% conversion rate. And their brand utilization rates (between 93% and 99%) revealed that despite generic availability, prescribers were overwhelmingly choosing brand name products.</p>
            <div class="tableau-viz" id="top-20-drugs">
                <div class='tableauPlaceholder' id='viz1770612581113' style='position: relative'><noscript><a href='#'><img alt='Top 20 - Savings OpportunitiesDrugs with highest savings potential from 25% brand to generic conversion ' src='https:&#47;&#47;public.tableau.com&#47;static&#47;images&#47;To&#47;Top20-SavingsOpportunities&#47;Sheet1&#47;1_rss.png' style='border: none' /></a></noscript><object class='tableauViz'  style='display:none;'><param name='host_url' value='https%3A%2F%2Fpublic.tableau.com%2F' /> <param name='embed_code_version' value='3' /> <param name='site_root' value='' /><param name='name' value='Top20-SavingsOpportunities&#47;Sheet1' /><param name='tabs' value='no' /><param name='toolbar' value='yes' /><param name='static_image' value='https:&#47;&#47;public.tableau.com&#47;static&#47;images&#47;To&#47;Top20-SavingsOpportunities&#47;Sheet1&#47;1.png' /> <param name='animate_transition' value='yes' /><param name='display_static_image' value='yes' /><param name='display_spinner' value='yes' /><param name='display_overlay' value='yes' /><param name='display_count' value='yes' /><param name='language' value='en-US' /></object></div>
                <script type='text/javascript'>
                    var divElement = document.getElementById('viz1770612581113');
                    var vizElement = divElement.getElementsByTagName('object')[0];
                    vizElement.style.width='100%';
                    vizElement.style.height=(divElement.offsetWidth*0.75)+'px';
                    var scriptElement = document.createElement('script');
                    scriptElement.src = 'https://public.tableau.com/javascripts/api/viz_v1.js';
                    vizElement.parentNode.insertBefore(scriptElement, vizElement);
                </script>
            </div>
            <h3>Beyond Insulin</h3>
            <p>The top 20 list extended beyond insulin to include other high-cost, high-volume medications where generics existed but weren't being prescribed despite FDA therapeutic equivalence certification.<a href="#source-3" class="citation" title="FDA Orange Book Guidance">3</a><a href="#source-5" class="citation" title="Congress.gov CRS Report">5</a></p>
        </div>
    </section>
    <section id="insulin-deep-dive">
        <div class="container">
            <h2>Deep Dive: The Insulin Story</h2>
            <h3>The Most Striking Finding</h3>
            <p>The insulin numbers demand closer examination. My analysis identified multiple insulin formulations in the top savings opportunities, all sharing one characteristic: brand utilization rates between 93% and 99%. This means that even when generic insulin versions were available and FDA-approved as therapeutically equivalent,<a href="#source-3" class="citation" title="FDA Orange Book Guidance">3</a><a href="#source-5" class="citation" title="Congress.gov CRS Report">5</a> prescribers were choosing brand name products in nearly every case.</p>
            <h3>The $35 Cap Paradox</h3>
            <p>Here's what makes this particularly notable: January 2023 marked the implementation of the Inflation Reduction Act's $35-per-month insulin cost cap for Medicare Part D enrollees.<a href="#source-8" class="citation" title="ASPE HHS, October 2023">8</a> This policy capped what beneficiaries paid out of pocket, making insulin more affordable for patients. But it didn't address which version of insulin was being prescribed (brand or generic). While patients were protected from high costs, Medicare was still bearing the full price differential between expensive brand name insulins and their therapeutically equivalent generic alternatives.</p>
            <div class="tableau-viz" id="insulin-analysis">
                <div class='tableauPlaceholder' id='viz1770612593766' style='position: relative'><noscript><a href='#'><img alt='High Brand Utilization Drugs Present the Greatest Savings Opportunity ' src='https:&#47;&#47;public.tableau.com&#47;static&#47;images&#47;Sc&#47;Scatter_17706119023770&#47;Scatter-BrandvsGeneric&#47;1_rss.png' style='border: none' /></a></noscript><object class='tableauViz'  style='display:none;'><param name='host_url' value='https%3A%2F%2Fpublic.tableau.com%2F' /> <param name='embed_code_version' value='3' /> <param name='site_root' value='' /><param name='name' value='Scatter_17706119023770&#47;Scatter-BrandvsGeneric' /><param name='tabs' value='no' /><param name='toolbar' value='yes' /><param name='static_image' value='https:&#47;&#47;public.tableau.com&#47;static&#47;images&#47;Sc&#47;Scatter_17706119023770&#47;Scatter-BrandvsGeneric&#47;1.png' /> <param name='animate_transition' value='yes' /><param name='display_static_image' value='yes' /><param name='display_spinner' value='yes' /><param name='display_overlay' value='yes' /><param name='display_count' value='yes' /><param name='language' value='en-US' /></object></div>
                <script type='text/javascript'>
                    var divElement = document.getElementById('viz1770612593766');
                    var vizElement = divElement.getElementsByTagName('object')[0];
                    vizElement.style.width='100%';
                    vizElement.style.height=(divElement.offsetWidth*0.75)+'px';
                    var scriptElement = document.createElement('script');
                    scriptElement.src = 'https://public.tableau.com/javascripts/api/viz_v1.js';
                    vizElement.parentNode.insertBefore(scriptElement, vizElement);
                </script>
            </div>
            <h3>The Policy Context Continued Evolving</h3>
            <p>The insulin landscape continued shifting throughout 2023 and beyond. In March 2023, manufacturer Eli Lilly announced plans to cap insulin prices at $35,<a href="#source-14" class="citation" title="PBS NewsHour, January 2024">14</a> with other manufacturers following suit.<a href="#source-23" class="citation" title="PBS NewsHour, January 2024">23</a> These were voluntary programs rather than systematic shifts toward generic prescribing. By 2025-2026, the Medicare Drug Price Negotiation Program's provisions began affecting insulin pricing dynamics,<a href="#source-12" class="citation" title="KFF Snapshot, October 2025">12</a> but the fundamental question remained: when generics exist, why weren't they being prescribed?</p>
            <h3>What This Reveals About the System</h3>
            <p>The insulin pattern illustrates a crucial insight: patient cost caps and manufacturer pricing agreements, while beneficial for beneficiary affordability, don't necessarily change prescribing behavior. The 93-99% brand utilization rates in 2023 suggest that even as policy interventions focused on lowering patient costs, the underlying practice of prescribing expensive brands over identical generics persisted. This represents a different kind of savings opportunity, one focused on system level efficiency rather than patient out of pocket costs.</p>
        </div>
    </section>
    <section id="finding-3">
        <div class="container">
            <h2>Key Finding #3: Geography Doesn't Explain It</h2>
            <h3>Testing the Regional Hypothesis</h3>
            <p>One plausible explanation for high brand utilization could have been regional variation. Perhaps certain states or regions had prescribing cultures that favored brand name drugs, while others embraced generics more readily. My analysis examined generic adoption rates across all 50 states plus U.S. territories to test this hypothesis.</p>
            <h3>Remarkably Narrow Variation</h3>
            <p>What I found was striking uniformity. Generic adoption rates across states ranged from 88.3% to 91.6%, a span of just 3.3 percentage points. This isn't the kind of variation that explains a multi-billion-dollar savings opportunity. Whether you looked at California or Wyoming, New York or Mississippi, the pattern was essentially the same: generics were widely adopted overall, but certain specific drugs showed persistently high brand utilization regardless of geography.</p>
            <div class="tableau-viz" id="state-map">
                <div class='tableauPlaceholder' id='viz1770612618826' style='position: relative'><noscript><a href='#'><img alt='State Level Generic Adoption RatesLower Rates (orange&#47;red) indicate higher savings opportunities ' src='https:&#47;&#47;public.tableau.com&#47;static&#47;images&#47;St&#47;State_17706124726000&#47;State-GenericAdoptionMap&#47;1_rss.png' style='border: none' /></a></noscript><object class='tableauViz'  style='display:none;'><param name='host_url' value='https%3A%2F%2Fpublic.tableau.com%2F' /> <param name='embed_code_version' value='3' /> <param name='site_root' value='' /><param name='name' value='State_17706124726000&#47;State-GenericAdoptionMap' /><param name='tabs' value='no' /><param name='toolbar' value='yes' /><param name='static_image' value='https:&#47;&#47;public.tableau.com&#47;static&#47;images&#47;St&#47;State_17706124726000&#47;State-GenericAdoptionMap&#47;1.png' /> <param name='animate_transition' value='yes' /><param name='display_static_image' value='yes' /><param name='display_spinner' value='yes' /><param name='display_overlay' value='yes' /><param name='display_count' value='yes' /><param name='language' value='en-US' /></object></div>
                <script type='text/javascript'>
                    var divElement = document.getElementById('viz1770612618826');
                    var vizElement = divElement.getElementsByTagName('object')[0];
                    vizElement.style.width='100%';
                    vizElement.style.height=(divElement.offsetWidth*0.75)+'px';
                    var scriptElement = document.createElement('script');
                    scriptElement.src = 'https://public.tableau.com/javascripts/api/viz_v1.js';
                    vizElement.parentNode.insertBefore(scriptElement, vizElement);
                </script>
            </div>
            <h3>What This Tells Us</h3>
            <p>The narrow geographic variation has important implications: the savings opportunity isn't primarily driven by regional prescribing differences or state level policy variations. Instead, the concentration of potential savings in specific high-cost drugs (particularly the insulin products with 93-99% brand utilization) suggests that the problem lies with particular medications rather than geographic patterns. An intervention to increase generic adoption in one state would likely face the same barriers as an intervention in any other state.</p>
            <h3>Implications for Solutions</h3>
            <p>This finding suggests that interventions to increase generic adoption would likely need to be drug specific rather than region specific. Rather than targeting states or regions with low generic adoption rates, efforts should focus on changing prescriber behavior for particular high-cost medications where generic alternatives exist but aren't being prescribed. The insulin case exemplifies this: the problem wasn't isolated to certain geographic areas. It was systemic across the entire Medicare Part D program.</p>
        </div>
    </section>
    <section id="the-why">
        <div class="container">
            <h2>The Why: Barriers to Generic Adoption</h2>
            <p>The data reveals <em>what</em> happened in 2023 (high brand utilization despite generic availability) but not <em>why</em>. Understanding the barriers to generic adoption requires examining the complex ecosystem of prescribers, patients, pharmacists, regulators, and payers. Research has identified several documented barriers that help explain the patterns observed in this analysis.</p>
            <h3>Perceptions & Psychology</h3>
            <p>Research has shown that barriers to generic drug use include negative perceptions about generic medicines, concerns about efficacy and safety, and preference for familiar brand names.<a href="#source-15" class="citation" title="ScienceDirect, December 2013">15</a> Studies of specific patient populations have documented concerns that generic substitution might lead to breakthrough symptoms or side effects,<a href="#source-16" class="citation" title="U.S. Pharmacist, June 2020">16</a> even though the FDA maintains that therapeutically equivalent generics are just as safe and effective as brand name drugs.<a href="#source-17" class="citation" title="FDA Generic Drugs">17</a> These perceptions affect both prescribers and patients: a prescriber may default to the brand name product they learned in medical school, while patients may request brand names they've seen advertised or used previously.</p>
            <h3>State Regulations & "Dispense as Written"</h3>
            <p>Barriers can occur at multiple points, including state laws on generic substitution, factors related to generic availability, and consumer and prescriber behavior.<a href="#source-18" class="citation" title="ASPE Expanding Generic Use">18</a> Some states require pharmacists to substitute generics unless the prescriber specifies otherwise, while others take a more permissive approach, allowing but not requiring substitution.<a href="#source-19" class="citation" title="ASPE Expanding Generic Use">19</a> Additionally, some states require patient consent before generic substitution.</p>
            <p>Prescribers can specify "dispense as written" (DAW) or "brand necessary," which overrides generic substitution laws. Research on specialty drugs has found that DAW specifications can be significantly higher than the general prescription population. One study of generic imatinib found 24% of prescriptions were marked DAW, compared to just 3.5% for medications with available generics overall.<a href="#source-20" class="citation" title="Health Affairs, May 2018">20</a></p>
            <h3>Pharmacy Benefit Manager Incentives</h3>
            <p>PBMs, which manage prescription drug benefits on behalf of insurers and employers, create formularies and negotiate rebates that can create counterintuitive barriers to lower-cost medicines.<a href="#source-21" class="citation" title="DrugPatentWatch, October 2025">21</a> The complex incentive structures can sometimes favor higher-cost drugs when rebates and other considerations are factored in. While the details of PBM negotiations are often proprietary, the structure can create situations where a higher-priced brand name drug might be preferred on a formulary despite a generic alternative being available.</p>
            <h3>The Complexity Factor</h3>
            <p>These barriers don't operate in isolation. They interact and compound. A prescriber concerned about patient preferences might write "dispense as written" to avoid pharmacy substitution. State laws that require patient consent add friction to generic substitution. PBM formularies that favor certain brands create economic incentives that run counter to generic adoption. The result is a system where the path of least resistance often leads to brand name prescriptions, even when therapeutically equivalent generics exist.</p>
        </div>
    </section>
    <section id="implications">
        <div class="container">
            <h2>What This Means: Insights & Implications</h2>
            <p>While the 2023 landscape has now been transformed by IRA provisions, this historical analysis offers insights that remain relevant as Medicare Part D continues to evolve. The patterns identified here (drug specific savings concentration, persistent high brand utilization despite generic availability, and minimal geographic variation) suggest several considerations for different stakeholders.</p>
            <div class="recommendation-grid">
                <div class="recommendation-card">
                    <h4>For Policy Makers</h4>
                    <p>The narrow geographic variation in generic adoption (88.3-91.6%) coupled with savings highly concentrated in specific drugs like insulin suggests that interventions should be drug specific rather than region specific. Research has shown that state level generic substitution laws affect adoption rates,<a href="#source-24" class="citation" title="PMC Pharmacist Regulations">24</a> yet the 2023 data reveals that even with varying state laws, high brand utilization persisted for certain medications across all geographies.</p>
                    <p>As the Medicare Drug Price Negotiation Program takes effect and Part D cost sharing structures continue to change, monitoring whether brand versus generic utilization patterns shift will be important for understanding policy effectiveness. The insulin case study from 2023 (where 93-99% brand utilization persisted even after the $35 cost cap took effect<a href="#source-8" class="citation" title="ASPE HHS, October 2023">8</a>) demonstrates that patient facing affordability measures don't automatically change prescribing behavior or system level costs.</p>
                </div>
                <div class="recommendation-card">
                    <h4>For Healthcare Providers</h4>
                    <p>The analysis underscores several opportunities for prescribers and pharmacists:</p>
                    <p><strong>Generic-first prescribing:</strong> When clinically appropriate, defaulting to generic prescriptions for therapeutically equivalent drugs<a href="#source-3" class="citation" title="FDA Orange Book Guidance">3</a><a href="#source-5" class="citation" title="Congress.gov CRS Report">5</a> can generate substantial system savings without compromising patient outcomes.</p>
                    <p><strong>Patient education:</strong> Pharmacists and prescribers explaining that FDA-rated "A" therapeutic equivalents deliver the same clinical outcomes<a href="#source-3" class="citation" title="FDA Orange Book Guidance">3</a><a href="#source-17" class="citation" title="FDA Generic Drugs">17</a> can help address perception barriers that discourage generic adoption.<a href="#source-15" class="citation" title="ScienceDirect, December 2013">15</a><a href="#source-16" class="citation" title="U.S. Pharmacist, June 2020">16</a></p>
                    <p><strong>Systematic review:</strong> Periodically reviewing established patients to identify opportunities for cost-effective generic switches, particularly for high-cost medications like insulin where brand utilization was found to be 93-99% in 2023.</p>
                </div>
                <div class="recommendation-card">
                    <h4>For Researchers</h4>
                    <p>This analysis points to several areas warranting further investigation:</p>
                    <p><strong>Prescriber decision-making:</strong> Qualitative research exploring why prescribers continue brand name prescribing despite generic availability could reveal intervention points not captured in administrative data.</p>
                    <p><strong>Post-IRA impact assessment:</strong> Comparing 2023 brand utilization patterns to 2025-2026 data would assess whether IRA provisions changed prescribing behavior or merely shifted who pays. The question isn't just whether patients pay less, but whether the system is using lower-cost therapeutically equivalent alternatives.</p>
                    <p><strong>Insulin-specific deep dive:</strong> The 93-99% brand utilization rates for insulin products in 2023 deserve targeted investigation. Understanding whether subsequent policy changes (manufacturer voluntary caps,<a href="#source-23" class="citation" title="PBS NewsHour, January 2024">23</a> negotiation program provisions,<a href="#source-12" class="citation" title="KFF Snapshot, October 2025">12</a> and Part D restructuring<a href="#source-10" class="citation" title="CMS Part D Proposed Rule">10</a>) have affected this pattern would provide valuable insights into policy effectiveness.</p>
                </div>
            </div>
        </div>
    </section>
    <section id="limitations">
        <div class="container">
            <h2>Limitations & Transparency</h2>
            <p>Like all analyses, this project has important limitations that should be understood when interpreting the findings:</p>
            <div class="callout warning">
                <h4>1. Dated Analysis</h4>
                <p>This analysis examines 2023 data. The Medicare Part D landscape has fundamentally changed due to IRA provisions implemented in 2024-2026, including the coverage gap elimination, $2,000 out of pocket cap, and Medicare Drug Price Negotiation Program.<a href="#source-10" class="citation" title="CMS Part D Proposed Rule">10</a><a href="#source-11" class="citation" title="CMS 2026 Policy Updates">11</a><a href="#source-12" class="citation" title="KFF Snapshot, October 2025">12</a> Current savings opportunities and brand utilization patterns may differ substantially from what existed in 2023.</p>
            </div>
            <div class="callout info">
                <h4>2. Clinical Considerations Not Captured</h4>
                <p>While FDA-rated therapeutic equivalence means generic drugs deliver the same clinical outcomes,<a href="#source-3" class="citation" title="FDA Orange Book Guidance">3</a><a href="#source-5" class="citation" title="Congress.gov CRS Report">5</a><a href="#source-17" class="citation" title="FDA Generic Drugs">17</a> individual patients may have legitimate reasons for continuing brand name medications. These include different inactive ingredients that may affect tolerability in sensitive individuals, established dosing with narrow therapeutic index (NTI) drugs where prescribers prefer consistency, and prior authorization or step therapy requirements that may complicate switching. The administrative data shows <em>what</em> was prescribed but not <em>why</em>.</p>
            </div>
            <div class="callout info">
                <h4>3. Simplified Savings Model</h4>
                <p>The savings calculations assume a straightforward cost differential between brand and generic drugs based on documented price gaps.<a href="#source-6" class="citation" title="U.S. Pharmacist, June 2020">6</a> In practice, Medicare Part D pricing involves complex negotiations, manufacturer rebates, and risk corridors that may affect actual realized savings. The modeled savings represent potential system level cost reductions, not guaranteed budget impacts.</p>
            </div>
            <div class="callout info">
                <h4>4. Missing Context on Prescribing Rationale</h4>
                <p>The data reveals prescribing patterns but not the clinical reasoning behind them. High brand utilization could reflect various factors: prescriber preference based on clinical experience, patient request, prior authorization requirements favoring certain products, or clinical considerations not captured in administrative data. The analysis identifies the pattern but cannot definitively explain all contributing factors.</p>
            </div>
        </div>
    </section>
    <section id="conclusion">
        <div class="container">
            <h2>The Bottom Line</h2>
            <h3>The Core Finding</h3>
            <p>This analysis of 2023 Medicare Part D data reveals that $57.3 billion was spent on 454 drugs with generic alternatives available, and that a 25% shift from brand to generic could have saved Medicare $3.84 billion in a single year. The opportunity was particularly concentrated in insulin products, where 93-99% brand utilization persisted despite generic availability and despite the $35 insulin cost cap that took effect in January 2023.<a href="#source-8" class="citation" title="ASPE HHS, October 2023">8</a></p>
            <h3>Historical Context Matters</h3>
            <p>These findings represent a historical snapshot of Medicare Part D immediately before major structural reforms took effect. The IRA's Part D redesign, out of pocket spending caps, and Medicare Drug Price Negotiation Program have fundamentally altered the landscape since 2023.<a href="#source-10" class="citation" title="CMS Part D Proposed Rule">10</a><a href="#source-11" class="citation" title="CMS 2026 Policy Updates">11</a><a href="#source-12" class="citation" title="KFF Snapshot, October 2025">12</a> However, this analysis demonstrates the scale of the generic adoption opportunity that existed in the prereform period and raises important questions about prescribing patterns, policy effectiveness, and system level cost management.</p>
            <h3>The Enduring Insight</h3>
            <p>As Medicare continues to evolve, the core insight remains relevant: when therapeutically equivalent generic drugs exist,<a href="#source-3" class="citation" title="FDA Orange Book Guidance">3</a><a href="#source-5" class="citation" title="Congress.gov CRS Report">5</a> ensuring their adoption represents one of the most straightforward pathways to controlling prescription drug spending while maintaining patient access to effective medications. The question this analysis raises isn't whether generic substitution works. The FDA has already certified these drugs as therapeutically equivalent.<a href="#source-17" class="citation" title="FDA Generic Drugs">17</a> The question is what barriers prevent it from happening more systematically, and whether policy reforms address prescribing behavior or simply shift who bears the cost.</p>
        </div>
    </section>
    <section id="methodology">
        <div class="container">
            <h2>Methodology & Data Notes</h2>
            <div class="collapsible-section">
                <button class="collapsible-toggle" onclick="toggleCollapsible()">
                    Click to expand detailed methodology
                </button>
                <div class="collapsible-content" id="methodologyContent">
                    <div class="collapsible-inner">
                        <h3>Data Sources & Access</h3>
                        <p>This analysis used two publicly available Centers for Medicare & Medicaid Services (CMS) datasets from 2023:</p>
                        <ul>
                            <li><strong>Medicare Part D Prescriber by Drug and Geography</strong> - Contains prescriber level information on drug spending, total claims, beneficiary counts, and geographic distribution across all 50 states plus U.S. territories.</li>
                            <li><strong>Medicare Part D Spending by Drug</strong> - Contains drug level aggregate spending data, including total program costs and beneficiary out of pocket costs.</li>
                        </ul>
                        <p>Both datasets are available through the CMS data portal and represent the most comprehensive publicly available information on Medicare Part D prescription activity.</p>
                        <h3>Technical Approach</h3>
                        <p>All data processing was conducted in Python using pandas for data manipulation, with analysis organized into seven separate scripts:</p>
                        <ol>
                            <li>Drug identification and classification</li>
                            <li>Brand vs. generic categorization</li>
                            <li>Utilization rate calculations</li>
                            <li>Savings scenario modeling</li>
                            <li>State-level geographic analysis</li>
                            <li>Data validation and cross-referencing</li>
                            <li>Tableau export file generation</li>
                        </ol>
                        <p>This modular approach allowed for transparent verification of each analysis phase and ensured reproducibility of results.</p>
                        <h3>Therapeutic Equivalence Verification</h3>
                        <p>All generic equivalents were verified against FDA Orange Book standards for therapeutic equivalence.<a href="#source-3" class="citation" title="FDA Orange Book Guidance">3</a><a href="#source-5" class="citation" title="Congress.gov CRS Report">5</a> Only drugs with FDA "A" ratings (indicating pharmaceutical equivalence, bioequivalence, and safe substitutability) were included in the analysis. The bioequivalence standard requires that 90% confidence intervals for generic to brand ratios of Cmax and AUC fall within 80-125%.<a href="#source-4" class="citation" title="Rx-wiki Orange Book">4</a></p>
                        <h3>Savings Calculation Methodology</h3>
                        <p>Potential savings were calculated using the formula:</p>
                        <p style="text-align: center; font-family: var(--font-mono); background-color: var(--bg-light); padding: 1rem; border-radius: 4px; margin: 1.5rem 0;"><strong>Savings = Brand Spending × Conversion Rate × Generic Discount Rate</strong></p>
                        <p>Where:</p>
                        <ul>
                            <li><strong>Brand Spending</strong> = Total 2023 Medicare spending on brand name versions of drugs with generic alternatives</li>
                            <li><strong>Conversion Rate</strong> = Percentage of brand prescriptions converted to generic (modeled at 10%, 25%, 50%, 75%, 100%)</li>
                            <li><strong>Generic Discount Rate</strong> = Conservative estimate based on documented 80-85% cost differential between brand and generic drugs<a href="#source-6" class="citation" title="U.S. Pharmacist, June 2020">6</a></li>
                        </ul>
                        <p>This approach models potential system level savings, not guaranteed budget impacts, as actual Medicare Part D pricing involves manufacturer rebates and risk corridors not fully captured in the public datasets.</p>
                        <h3>Data Validation</h3>
                        <p>All calculations underwent multiple validation checks:</p>
                        <ul>
                            <li><strong>Mathematical consistency:</strong> Cross-verified that totals matched across all seven output files</li>
                            <li><strong>CMS reconciliation:</strong> Compared aggregate spending totals to published CMS figures for 2023</li>
                            <li><strong>Referential integrity:</strong> Ensured drug names, classifications, and identifiers remained consistent across datasets</li>
                            <li><strong>Outlier review:</strong> Flagged and manually verified drugs with unusual utilization patterns or cost structures</li>
                        </ul>
                        <h3>Output Files for Visualization</h3>
                        <p>The analysis produced seven Tableau-ready CSV files:</p>
                        <ol>
                            <li><code>tableau_top20_drugs.csv</code> - Top 20 drugs by savings potential</li>
                            <li><code>tableau_all_drugs.csv</code> - All 454 drugs with categorizations</li>
                            <li><code>tableau_savings_scenarios.csv</code> - Savings at multiple conversion rates</li>
                            <li><code>tableau_state_analysis.csv</code> - State-level generic adoption rates</li>
                            <li><code>tableau_brand_vs_generic_costs.csv</code> - Cost per claim comparisons</li>
                            <li><code>tableau_summary_stats.csv</code> - Key statistics for dashboard KPIs</li>
                            <li><code>tableau_insulin_analysis.csv</code> - Insulin-specific deep dive</li>
                        </ol>
                        <h3>Limitations of Public Data</h3>
                        <p>The CMS public datasets provide comprehensive coverage but have some limitations:</p>
                        <ul>
                            <li><strong>Aggregate data:</strong> Individual patient level clinical decisions are not visible</li>
                            <li><strong>Rebate information:</strong> Manufacturer rebates to Part D plans are not included in public files</li>
                            <li><strong>Prior authorization:</strong> Data doesn't indicate whether brand prescriptions resulted from PA requirements</li>
                            <li><strong>Provider specialty:</strong> Limited information on prescriber specialty or practice setting</li>
                        </ul>
                        <p>These limitations are inherent to working with publicly available administrative data and affect what questions can be definitively answered.</p>
                    </div>
                </div>
            </div>
        </div>
    </section>
    <section id="sources">
        <div class="container">
            <h2>Sources</h2>
            <p>All factual claims in this analysis are supported by the following sources:</p>
            <ol class="sources-list">
                <li id="source-1" data-number="1.">Kaiser Family Foundation (KFF). "A Current Snapshot of the Medicare Part D Prescription Drug Benefit." October 2025. <a href="https://www.kff.org/medicare/a-current-snapshot-of-the-medicare-part-d-prescription-drug-benefit/" target="_blank">https://www.kff.org/medicare/a-current-snapshot-of-the-medicare-part-d-prescription-drug-benefit/</a></li>
                <li id="source-2" data-number="2.">Centers for Medicare & Medicaid Services (CMS). "Prescription Drug Coverage - General Information." <a href="https://www.cms.gov/medicare/coverage/prescription-drug-coverage" target="_blank">https://www.cms.gov/medicare/coverage/prescription-drug-coverage</a></li>
                <li id="source-3" data-number="3.">U.S. Food and Drug Administration (FDA). "Orange Book Questions and Answers Guidance for Industry." <a href="https://www.fda.gov/media/160167/download" target="_blank">https://www.fda.gov/media/160167/download</a></li>
                <li id="source-4" data-number="4.">Rx-wiki. "Orange Book." <a href="http://rx-wiki.org/index.php?title=Orange_Book" target="_blank">http://rx-wiki.org/index.php?title=Orange_Book</a></li>
                <li id="source-5" data-number="5.">Congress.gov. "Patent Listing in FDA's Orange Book." Congressional Research Service (CRS) Report. <a href="https://www.congress.gov/crs-product/IF12644" target="_blank">https://www.congress.gov/crs-product/IF12644</a></li>
                <li id="source-6" data-number="6.">U.S. Pharmacist. "Discussing Brand Versus Generic Medications." June 2020. <a href="https://www.uspharmacist.com/article/discussing-brand versus generic-medications" target="_blank">https://www.uspharmacist.com/article/discussing-brand versus generic-medications</a></li>
                <li id="source-7" data-number="7.">U.S. Pharmacist. "Discussing Brand Versus Generic Medications." June 2020. <a href="https://www.uspharmacist.com/article/discussing-brand versus generic-medications" target="_blank">https://www.uspharmacist.com/article/discussing-brand versus generic-medications</a></li>
                <li id="source-8" data-number="8.">Office of the Assistant Secretary for Planning and Evaluation (ASPE), U.S. Department of Health and Human Services. "Insulin Affordability and the Inflation Reduction Act." October 2023. <a href="https://www.ncbi.nlm.nih.gov/books/NBK616488/" target="_blank">https://www.ncbi.nlm.nih.gov/books/NBK616488/</a></li>
                <li id="source-9" data-number="9.">Office of the Assistant Secretary for Planning and Evaluation (ASPE), U.S. Department of Health and Human Services. "Insulin Affordability and the Inflation Reduction Act." October 2023. <a href="https://www.ncbi.nlm.nih.gov/books/NBK616488/" target="_blank">https://www.ncbi.nlm.nih.gov/books/NBK616488/</a></li>
                <li id="source-10" data-number="10.">Centers for Medicare & Medicaid Services (CMS). "Contract Year 2027 Medicare Advantage and Part D Proposed Rule." Fact Sheet. <a href="https://www.cms.gov/newsroom/fact-sheets/contract-year-2027-medicare-advantage-part-d-proposed-rule" target="_blank">https://www.cms.gov/newsroom/fact-sheets/contract-year-2027-medicare-advantage-part-d-proposed-rule</a></li>
                <li id="source-11" data-number="11.">Centers for Medicare & Medicaid Services (CMS). "CMS Releases Proposed 2026 Payment Policy Updates." Press Release. <a href="https://www.cms.gov/newsroom/press-releases/cms-releases-proposed-2026-payment-policy-updates-medicare-advantage-and-part-d-programs" target="_blank">https://www.cms.gov/newsroom/press-releases/cms-releases-proposed-2026-payment-policy-updates-medicare-advantage-and-part-d-programs</a></li>
                <li id="source-12" data-number="12.">Kaiser Family Foundation (KFF). "A Current Snapshot of the Medicare Part D Prescription Drug Benefit." October 2025. <a href="https://www.kff.org/medicare/a-current-snapshot-of-the-medicare-part-d-prescription-drug-benefit/" target="_blank">https://www.kff.org/medicare/a-current-snapshot-of-the-medicare-part-d-prescription-drug-benefit/</a></li>
                <li id="source-13" data-number="13.">AARP. "What to Know About Medicare's Insulin Costs." June 2025. <a href="https://www.aarp.org/advocacy/medicare-insulin-questions-answers-2023/" target="_blank">https://www.aarp.org/advocacy/medicare-insulin-questions-answers-2023/</a></li>
                <li id="source-14" data-number="14.">PBS NewsHour. "New law caps insulin prices for some with diabetes." January 2024. <a href="https://www.pbs.org/newshour/show/new-law-caps-insulin-prices-for-some-with-diabetes-but-cost-remains-high-for-millions" target="_blank">https://www.pbs.org/newshour/show/new-law-caps-insulin-prices-for-some-with-diabetes-but-cost-remains-high-for-millions</a></li>
                <li id="source-15" data-number="15.">ScienceDirect. "The experiences of implementing generic medicine policy in eight countries." December 2013. <a href="https://www.sciencedirect.com/science/article/pii/S131901641300128X" target="_blank">https://www.sciencedirect.com/science/article/pii/S131901641300128X</a></li>
                <li id="source-16" data-number="16.">U.S. Pharmacist. "Discussing Brand Versus Generic Medications." June 2020. <a href="https://www.uspharmacist.com/article/discussing-brand versus generic-medications" target="_blank">https://www.uspharmacist.com/article/discussing-brand versus generic-medications</a></li>
                <li id="source-17" data-number="17.">U.S. Food and Drug Administration (FDA). "Generic Drugs." <a href="https://www.fda.gov/drugs/buying-using-medicine-safely/generic-drugs" target="_blank">https://www.fda.gov/drugs/buying-using-medicine-safely/generic-drugs</a></li>
                <li id="source-18" data-number="18.">Office of the Assistant Secretary for Planning and Evaluation (ASPE), U.S. Department of Health and Human Services. "Expanding the Use of Generic Drugs." <a href="https://aspe.hhs.gov/reports/expanding-use-generic-drugs-0" target="_blank">https://aspe.hhs.gov/reports/expanding-use-generic-drugs-0</a></li>
                <li id="source-19" data-number="19.">Office of the Assistant Secretary for Planning and Evaluation (ASPE), U.S. Department of Health and Human Services. "Expanding the Use of Generic Drugs." <a href="https://aspe.hhs.gov/reports/expanding-use-generic-drugs-0" target="_blank">https://aspe.hhs.gov/reports/expanding-use-generic-drugs-0</a></li>
                <li id="source-20" data-number="20.">Health Affairs. "Generic Price Competition For Specialty Drugs: Too Little, Too Late?" May 2018. <a href="https://www.healthaffairs.org/doi/10.1377/hlthaff.2017.1684" target="_blank">https://www.healthaffairs.org/doi/10.1377/hlthaff.2017.1684</a></li>
                <li id="source-21" data-number="21.">DrugPatentWatch. "The Patent Cliff and Beyond." October 2025. <a href="https://www.drugpatentwatch.com/blog/generic-drug-entry-timeline-predicting-market-dynamics-after-patent-loss/" target="_blank">https://www.drugpatentwatch.com/blog/generic-drug-entry-timeline-predicting-market-dynamics-after-patent-loss/</a></li>
                <li id="source-22" data-number="22.">Healthline. "Medicare Insulin Cap." August 2025. <a href="https://www.healthline.com/health/medicare/is-there-a-price-ceiling-on-insulin" target="_blank">https://www.healthline.com/health/medicare/is-there-a-price-ceiling-on-insulin</a></li>
                <li id="source-23" data-number="23.">PBS NewsHour. "New law caps insulin prices for some with diabetes." January 2024. <a href="https://www.pbs.org/newshour/show/new-law-caps-insulin-prices-for-some-with-diabetes-but-cost-remains-high-for-millions" target="_blank">https://www.pbs.org/newshour/show/new-law-caps-insulin-prices-for-some-with-diabetes-but-cost-remains-high-for-millions</a></li>
                <li id="source-24" data-number="24.">PubMed Central (PMC), National Library of Medicine. "The effects of state level pharmacist regulations on generic substitution." <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6172151/" target="_blank">https://pmc.ncbi.nlm.nih.gov/articles/PMC6172151/</a></li>
            </ol>
            <h3 style="margin-top: 3rem;">Data Sources</h3>
            <p><strong>Centers for Medicare & Medicaid Services (CMS) Public Datasets (2023):</strong></p>
            <ul>
                <li>Medicare Part D Prescriber by Drug and Geography</li>
                <li>Medicare Part D Spending by Drug</li>
            </ul>
            <p>Available at: <a href="https://data.cms.gov/" target="_blank">https://data.cms.gov/</a></p>
        </div>
    </section>
    <footer>
        <div class="container">
            <p><strong>Medicare Part D Generic Drug Analysis</strong></p>
            <p>Portfolio Project by Aiden Jajo | Data Analytics • Python • Tableau</p>
            <p style="margin-top: 2rem; font-size: 0.9rem; opacity: 0.7;">Analysis conducted February 2026 using 2023 Medicare Part D data<br>
            <a href="https://aidenjajo.com">← Return to main portfolio</a></p>
        </div>
    </footer>
    <script>
        // Collapsible methodology section
        function toggleCollapsible() {
            const toggle = document.querySelector('.collapsible-toggle');
            const content = document.getElementById('methodologyContent');
            toggle.classList.toggle('active');
            content.classList.toggle('active');
        }
        // Smooth scrolling for anchor links
        document.querySelectorAll('a[href^="#"]').forEach(anchor => {
            anchor.addEventListener('click', function (e) {
                const href = this.getAttribute('href');
                // Only smooth scroll for section links, not citation links
                if (href.startsWith('#source-')) {
                    return; // Let citation links work normally
                }
                e.preventDefault();
                const target = document.querySelector(href);
                if (target) {
                    target.scrollIntoView({
                        behavior: 'smooth',
                        block: 'start'
                    });
                }
            });
        });
    </script>
</body>
</html>
